Xalkori

Xalkori is a brand name of crizotinib, approved by the FDA in the following formulation(s):

XALKORI (crizotinib - capsule; oral)

• 
  Manufacturer: PFIZER
  
  Approval date: August 26, 2011
  
  Strength(s): 200MG, 250MG ^[RLD]

Has a generic version of Xalkori been approved?

No. There is currently no therapeutically equivalent version of Xalkori available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xalkori. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aminoheteroaryl compounds as protein kinase inhibitors
  Patent 7,230,098
  Issued: June 12, 2007
  Inventor(s): Cui; Jingrong Jean & Bhumralkar; Dilip & Botrous; Iriny & Chu; Ji Yu & Funk; Lee A. & Hanau; Cathleen Elizabeth & Harris; G. Davis & Jia; Lei & Johnson; Joanne & Kolodziej; Stephen A. & Kung; Pei-Pei & Li; Xiaoyuan (Sharon) & Lin; Jason (Qishen) & Meng; Jerry Jialun & Nambu; Mitchel
  Assignee(s): Sugen, Inc.
  Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET
  
  Patent expiration dates:
  
  
  • March 1, 2025
    
    ✓ 
    Drug substance
  
  



• 
  Method of treating abnormal cell growth
  Patent 7,825,137
  Issued: November 2, 2010
  Inventor(s): Christensen; James Gail & Zou; Yahong
  Assignee(s): Pfizer Inc.
  The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer.
  
  Patent expiration dates:
  
  
  • May 12, 2027
    
    ✓ 
    Patent use: TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
  
  



• 
  Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
  Patent 7,858,643
  Issued: December 28, 2010
  Inventor(s): Cui; Jingrong Jean & Funk; Lee Andrew & Jia; Lei & Kung; Pei-Pei & Meng; Jerry Jialun & Nambu; Mitchell David & Pairish; Mason Alan & Shen; Hong & Tran-Dube; Michelle
  Assignee(s): Agouron Pharmaceuticals, Inc.
  Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
  
  Patent expiration dates:
  
  
  • October 8, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 26, 2016 - NEW CHEMICAL ENTITY
  
  
  • August 26, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Xalkori Consumer Information (Drugs.com)
• Xalkori Consumer Information (Wolters Kluwer)
• Xalkori Consumer Information (Cerner Multum)
• Crizotinib Consumer Information (Wolters Kluwer)
• Crizotinib Consumer Information (Cerner Multum)